EGM
SYRE icon

Engineers Gate Manager’s Spyre Therapeutics SYRE Stock Holding History

Engineers Gate Manager’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,653
Closed -$594K – 2232
2024
Q1 		$594K Buy
+15,653
New +$454K 0.02% 1110
2022
Q1 		– Sell
-600
Closed -$71K – 2296
2021
Q4 		$71K Buy
+600
New +$94.7K ﹤0.01% 1836
2021
Q2 		– Sell
-432
Closed -$86K – 2004
2021
Q1 		$86K Buy
+432
New +$82.9K ﹤0.01% 1723
2020
Q4 		– Sell
-576
Closed -$102K – 1975
2020
Q3 		$102K Buy
+576
New +$107K ﹤0.01% 1553

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Engineers Gate Manager's SYRE Position: Q2 2024 in Review

Engineers Gate Manager sold out of Spyre Therapeutics (SYRE) in Q2 2024, closing a stake of 15,653 shares — an estimated $594K sold.

Engineers Gate Manager first reported a position in SYRE in Q3 2020 and held it in 4 quarters. The position peaked at $594K in Q1 2024. 107 funds tracked by Wall St. Rank hold SYRE as of Q2 2024.

  • Engineers Gate Manager reported no remaining Spyre Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Engineers Gate Manager sold 15,653 Spyre Therapeutics shares in Q2 2024, an estimated $594K.
  • Engineers Gate Manager first reported a position in Spyre Therapeutics in Q3 2020 and held it in 4 quarters.
  • Engineers Gate Manager's Spyre Therapeutics position peaked at $594K in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2024.

Based on Engineers Gate Manager's 13F filing for Q2 2024, filed 14 Aug 2024.